TY - JOUR
T1 - Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer
AU - Frattini, Milo
AU - Ferrario, Cristina
AU - Bressan, Paola
AU - Balestra, Debora
AU - De Cecco, Loris
AU - Mondellini, Piera
AU - Bongarzone, Italia
AU - Collini, Paola
AU - Gariboldi, Manuela
AU - Pilotti, Silvana
AU - Pierotti, Marco A.
AU - Greco, Angela
PY - 2004/9/23
Y1 - 2004/9/23
N2 - Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression profiling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.
AB - Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression profiling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.
KW - BRAF mutation
KW - Papillary thyroid cancer
KW - RET and TRK rearrangement
UR - http://www.scopus.com/inward/record.url?scp=6044219917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=6044219917&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1207980
DO - 10.1038/sj.onc.1207980
M3 - Article
C2 - 15273715
AN - SCOPUS:6044219917
SN - 0950-9232
VL - 23
SP - 7436
EP - 7440
JO - Oncogene
JF - Oncogene
IS - 44
ER -